These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 31977260

  • 1. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis.
    Abdelhafeez AAM, Shohdy KS, Ibrahim W.
    Cancer Invest; 2020 Mar; 38(3):150-157. PubMed ID: 31977260
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis.
    Rangwala HS, Fatima H, Ali M, Sunder S, Devi S, Rangwala BS, Abbas SR.
    J Egypt Natl Canc Inst; 2024 May 06; 36(1):14. PubMed ID: 38705953
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
    D'Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK, Streicher H.
    Lancet Oncol; 2018 Mar 06; 19(3):416-426. PubMed ID: 29370992
    [Abstract] [Full Text] [Related]

  • 6. Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta-analysis.
    Mao YT, Wang Y, Chen XX, Liu CJ, Bao Q.
    J Cosmet Dermatol; 2024 Apr 06; 23(4):1165-1177. PubMed ID: 38013634
    [Abstract] [Full Text] [Related]

  • 7. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
    Irwin DE, Davis B, Bell JA, Galaznik A, Garcia-Ribas I.
    J Comp Eff Res; 2019 Jan 06; 8(2):81-90. PubMed ID: 30547675
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis.
    Mei T, Wang T, Deng Q, Gong Y.
    Front Immunol; 2023 Jan 06; 14():1062679. PubMed ID: 36825025
    [Abstract] [Full Text] [Related]

  • 12. Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.
    Maeda T, Hiura A, Uehara J, Toyoshima R, Nakagawa T, Yoshino K.
    Eur J Dermatol; 2021 Oct 01; 31(5):662-664. PubMed ID: 34642136
    [No Abstract] [Full Text] [Related]

  • 13. Adverse Events Induced by Nivolumab Plus Ipilimumab vs. Nivolumab Monotherapy among Cancer Patients: A Systematic Review and Meta-Analysis.
    Kamat S, Patel J, Brown BR, Vyas A.
    Cancer Invest; 2022 Oct 01; 40(9):777-788. PubMed ID: 35916661
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis.
    Mangla A, Lee C, Mirsky MM, Wang M, Rothermel LD, Hoehn R, Bordeaux JS, Carroll BT, Theuner J, Li S, Fu P, Kirkwood JM.
    JAMA Oncol; 2024 May 01; 10(5):612-620. PubMed ID: 38546551
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.